PYNNACLE Study | Rezatapopt | PYNNACLE clinical study

Rezatapopt, an investigational oral p53 reactivator targeting TP53 Y220C mutations, is under study in the PYNNACLE Phase 1/2 trial for solid tumors. Phase 1 assessed safety, pharmacokinetics, and efficacy; Phase 1b evaluated its combination with pembrolizumab. Phase 2, currently enrolling, focuses on rezatapopt's efficacy and safety.